Hologic, Inc. (NASDAQ:HOLX) Shares Sold by SVB Wealth LLC

SVB Wealth LLC cut its position in Hologic, Inc. (NASDAQ:HOLX) by 17.6% in the fourth quarter, Holdings Channel reports. The firm owned 19,204 shares of the medical equipment provider’s stock after selling 4,090 shares during the period. SVB Wealth LLC’s holdings in Hologic were worth $1,372,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. McGlone Suttner Wealth Management Inc. acquired a new stake in shares of Hologic in the 4th quarter valued at about $27,000. Venturi Wealth Management LLC acquired a new stake in shares of Hologic in the 3rd quarter valued at about $29,000. Bartlett & CO. Wealth Management LLC acquired a new stake in shares of Hologic in the 4th quarter valued at about $33,000. NBC Securities Inc. acquired a new stake in shares of Hologic in the 3rd quarter valued at about $33,000. Finally, Clear Street Markets LLC boosted its position in shares of Hologic by 91.3% in the 1st quarter. Clear Street Markets LLC now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after purchasing an additional 231 shares during the period. 94.73% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Needham & Company LLC reissued a “buy” rating and issued a $90.00 target price on shares of Hologic in a research report on Wednesday, April 10th. Evercore ISI increased their price objective on Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a research report on Thursday, April 4th. William Blair reaffirmed an “outperform” rating on shares of Hologic in a research report on Friday, February 2nd. Raymond James increased their price objective on Hologic from $85.00 to $88.00 and gave the stock an “outperform” rating in a research report on Friday, February 2nd. Finally, StockNews.com cut Hologic from a “buy” rating to a “hold” rating in a research report on Friday, March 8th. Six research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $87.00.

Hologic Stock Performance

Shares of HOLX stock opened at $75.10 on Friday. The company has a market cap of $17.63 billion, a price-to-earnings ratio of 35.59, a price-to-earnings-growth ratio of 2.54 and a beta of 1.00. The stock has a 50 day simple moving average of $75.71 and a 200-day simple moving average of $72.50. Hologic, Inc. has a 12-month low of $64.02 and a 12-month high of $87.88. The company has a current ratio of 3.89, a quick ratio of 3.18 and a debt-to-equity ratio of 0.55.

Hologic (NASDAQ:HOLX) last issued its earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.95 by $0.03. Hologic had a return on equity of 18.91% and a net margin of 12.98%. The business had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $989.32 million. During the same period in the prior year, the business posted $1.07 EPS. The company’s revenue for the quarter was down 5.7% on a year-over-year basis. On average, equities analysts forecast that Hologic, Inc. will post 4.01 EPS for the current year.

Insider Activity at Hologic

In related news, Director Charles J. Dockendorff sold 1,465 shares of the firm’s stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $76.21, for a total value of $111,647.65. Following the completion of the transaction, the director now directly owns 1,572 shares of the company’s stock, valued at approximately $119,802.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Hologic news, CFO Karleen Marie Oberton sold 14,940 shares of the stock in a transaction on Monday, January 29th. The stock was sold at an average price of $75.00, for a total transaction of $1,120,500.00. Following the sale, the chief financial officer now owns 103,916 shares in the company, valued at approximately $7,793,700. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Charles J. Dockendorff sold 1,465 shares of the stock in a transaction on Friday, March 8th. The shares were sold at an average price of $76.21, for a total value of $111,647.65. Following the sale, the director now owns 1,572 shares in the company, valued at approximately $119,802.12. The disclosure for this sale can be found here. Insiders sold 32,846 shares of company stock valued at $2,473,443 in the last ninety days. Corporate insiders own 1.75% of the company’s stock.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.